Pentixapharm Holding AG (FRA:PTP) Total Equity: €32.15 Mil (As of Mar. 2026)


FRA:PTP Pentixapharm Holding AG FRA:PTP
20 GF Score
Price €2.20
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG Total Equity?

Pentixapharm Holding AG FRA:PTP -4.35% 20 Total Equity is €32.15 Mil as of Mar. 2026. GuruFocus rates FRA:PTP with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Pentixapharm Holding AG's total equity for the quarter that ended in Mar. 2026 was €32.15 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Pentixapharm Holding AG Total Equity Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG Total Equity Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
27.88 38.47 48.48 50.33 35.07

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 45.40 41.01 36.72 35.07 32.15
FRA:PTP
20GF Score
Pentixapharm Holding AG FRA:PTP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Pentixapharm Holding AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=41.859-6.787
=35.07

Pentixapharm Holding AG's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=41.168-9.016
=32.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €32.15 Mil mean?
Pentixapharm Holding AG (FRA:PTP) has a Total Equity of €32.15 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Pentixapharm Holding AG and its competitors.
Is Pentixapharm Holding AG's Total Equity too high?
Pentixapharm Holding AG's current Total Equity is €32.15 Mil. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Total Equity compare to VRTX and REGN?
Pentixapharm Holding AG's Total Equity of €32.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current Total Equity is €32.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current Total Equity of €32.15 Mil. The current Total Equity is €32.15 Mil. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current Total Equity is €32.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTP:GermanyPTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for FRA:PTP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.20
Price